Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Accounts Payables (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Accounts Payables for 6 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables fell 79.17% to $3.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.1 million, a 79.17% decrease, with the full-year FY2025 number at $3.1 million, down 79.17% from a year prior.
  • Accounts Payables was $3.1 million for Q4 2025 at Lexicon Pharmaceuticals, down from $3.8 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $14.8 million in Q4 2024 to a low of $3.1 million in Q4 2025.
  • A 3-year average of $10.0 million and a median of $10.6 million in 2023 define the central range for Accounts Payables.
  • Biggest YoY gain for Accounts Payables was 32.5% in 2025; the steepest drop was 79.17% in 2025.
  • Lexicon Pharmaceuticals' Accounts Payables stood at $14.4 million in 2023, then rose by 2.86% to $14.8 million in 2024, then crashed by 79.17% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Accounts Payables are $3.1 million (Q4 2025), $3.8 million (Q3 2025), and $5.9 million (Q2 2025).